Defilade Capital Management L.P. Purchases 805,982 Shares of Ocular Therapeutix, Inc. $OCUL

Posted by Brenda Bartman on Aug 3rd, 2026

Defilade Capital Management L.P. grew its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 118.2% during the 1st quarter, HoldingsChannel reports. The firm owned 1,487,645 shares of the biopharmaceutical company’s stock after purchasing an additional 805,982 shares during the quarter. Ocular Therapeutix comprises about 1.8% of Defilade Capital Management L.P.’s portfolio, making the stock its 25th largest holding. Defilade Capital Management L.P.’s holdings in Ocular Therapeutix were worth $12,600,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in OCUL. Empire Life Investments Inc. raised its stake in Ocular Therapeutix by 115.0% during the 4th quarter. Empire Life Investments Inc. now owns 540,115 shares of the biopharmaceutical company’s stock worth $6,557,000 after buying an additional 288,853 shares during the period. Candriam S.C.A. grew its stake in Ocular Therapeutix by 12.8% in the first quarter. Candriam S.C.A. now owns 949,216 shares of the biopharmaceutical company’s stock valued at $8,040,000 after acquiring an additional 107,614 shares during the period. Octagon Capital Advisors LP grew its stake in Ocular Therapeutix by 20.7% in the first quarter. Octagon Capital Advisors LP now owns 3,166,600 shares of the biopharmaceutical company’s stock valued at $26,821,000 after acquiring an additional 543,000 shares during the period. Prescott Group Capital Management L.L.C. bought a new stake in shares of Ocular Therapeutix in the fourth quarter worth about $3,800,000. Finally, Pictet Asset Management Holding SA increased its holdings in shares of Ocular Therapeutix by 1,229.6% in the first quarter. Pictet Asset Management Holding SA now owns 362,596 shares of the biopharmaceutical company’s stock worth $3,071,000 after acquiring an additional 335,324 shares in the last quarter. 59.21% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on OCUL shares. Robert W. Baird raised their price target on Ocular Therapeutix from $24.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Zacks Research lowered Ocular Therapeutix from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Friday, July 17th. Needham & Company LLC restated a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a report on Tuesday, May 5th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Ocular Therapeutix in a research note on Wednesday, May 6th. Twelve research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Ocular Therapeutix presently has an average rating of “Moderate Buy” and a consensus price target of $25.11.

View Our Latest Stock Report on Ocular Therapeutix

Insider Activity

In other news, insider Pravin Dugel sold 21,156 shares of Ocular Therapeutix stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total value of $173,479.20. Following the sale, the insider directly owned 2,597,170 shares in the company, valued at $21,296,794. This trade represents a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 28,999 shares of company stock valued at $237,792 in the last 90 days. 3.10% of the stock is owned by company insiders.

Ocular Therapeutix Stock Performance

NASDAQ OCUL opened at $8.17 on Monday. Ocular Therapeutix, Inc. has a 52 week low of $6.23 and a 52 week high of $16.44. The company has a debt-to-equity ratio of 0.12, a quick ratio of 14.73 and a current ratio of 14.81. The stock’s 50 day moving average price is $9.15 and its two-hundred day moving average price is $9.18. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -5.60 and a beta of 0.93.

Ocular Therapeutix Company Profile

(Free Report)

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.